{"entity":{"id":"nct07150104","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","aka":[],"tldr":"A phase 1/2 trial of Belantamab mafodotin, Nirogacestat, Pomalidomide in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.","summary":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM is a phase 1/2 interventional study registered as NCT07150104 by GlaxoSmithKline, with 14 participants enrolled, started 2022-08-31 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Nirogacestat, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07150104","url":"https://clinicaltrials.gov/study/NCT07150104"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["adc","antiemetic-therapy","gamma-secretase-inhibitors","kinase-inhibitors","protac-degrader"],"targets":[],"drugs":["belantamab-mafodotin","nirogacestat","pomalidomide","dexamethasone"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07150104","phase":"1/2","setting":"A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 7 - Belantamab Mafodotin, Nirogacestat, Pomalidomide, and Dexamethasone in Combination","sponsor":"GlaxoSmithKline","started":"2022-08-31","startedType":"actual","yearReported":2026,"enrolled":14,"enrolledBasis":"registry","outcomes":[{"endpoint":"DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs)","primary":true,"unit":"participants","arms":[{"name":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone","n":11,"value":2,"note":"Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT07150104?tab=results"},{"endpoint":"DE Phase: Overall Response Rate (ORR)","unit":"%","arms":[{"name":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone","n":14,"value":57,"note":"95% CI 28.9 to 82.3; Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT07150104?tab=results"}]},"route":"/trials/nct07150104/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"},{"id":"gamma-secretase-inhibitors","kind":"technology","name":"Gamma-secretase inhibitors","route":"/technologies/gamma-secretase-inhibitors/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}